Clinical Trials

Diffuse Intrinsic Pontine Glioma

NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Phase 1 Recruiting

58 enrolled

GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

Phase 2 Withdrawn

Meningioma

NCT03932643 2026-01-20

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

MyeloidOther hematologic neoplasm

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05009992 2025-12-17

PNOC022

Phase 2 Recruiting

360 enrolled

Diffuse Intrinsic Pontine Glioma

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

73 enrolled 13 charts 1 FDA

Glioma

NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Phase 2 Recruiting

62 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Phase 1 Terminated

134 enrolled 1 FDA

Diffuse Intrinsic Pontine Glioma, Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

84 enrolled 14 charts 1 FDA

Glioblastoma

NCT03099499 2024-12-24

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

19 enrolled

Gynecologic

Endometrial Neoplasms

NCT03485729 2024-12-24

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

27 enrolled 11 charts

Gynecologic

Endometrial Cancer Recurrent

NCT03034200 2024-11-26

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Phase 2 Completed

30 enrolled 12 charts

EndocrineNET

Neuroendocrine Tumors

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

17 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT04629209 2023-11-24

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Phase 2 Withdrawn

Glioblastoma

NCT03791398 2023-02-17

379

13 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Phase 2 Completed

30 enrolled 15 charts

BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02420795 2022-04-04

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

16 enrolled 14 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03733119 2022-03-10

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

4 enrolled 10 charts

Breast

Triple Negative Breast Neoplasms

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

BreastCNSGastrointestinalThoracic

33 enrolled

Plasma cell

Multiple Myeloma

NCT04854044 2021-05-12

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Phase 1 Withdrawn

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02038699 2021-04-30

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Phase 1/2 Withdrawn

Advanced Glioblastoma

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

5 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02250781 2019-05-22

Oral ONC201 in Treating Patients With Advanced Solid Tumors

58 enrolled

Other solid neoplasm

Solid Tumors

NCT02324621 2019-05-22

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors